News
Public · Published
Halozyme Therapeutics (HALO) Q3 earnings report preview: what to look for
Halozyme Therapeutics is scheduled to report its third-quarter earnings after market close on Thursday. Analysts expect revenue to grow 37.3% year on year, while estimates were generally unchanged over the prior 30 days. Last quarter, revenue was $481 million, up 47.7% from a year earlier, and beat analysts' expectations.
Published:
Updated:
What happened
Halozyme Therapeutics is scheduled to report its third-quarter earnings after market close on Thursday. Analysts expect revenue to grow 37.3% year on year, while estimates were generally unchanged over the prior 30 days. Last quarter, revenue was $481 million, up 47.7% from a year earlier, and beat analysts’ expectations.
Confirmed
Global impact / market context
The report will show whether Halozyme’s sales growth is continuing at the pace analysts expect. Revenue above or below the 37.3% forecast could change investors’ views of future income and the company’s ability to sustain growth, while the figures alone do not establish profitability or cash available.
Analyst inference
Analysts have generally kept their estimates steady over the last 30 days, indicating expectations have not shifted much ahead of the report. Biogen and Amgen have already reported revenue growth and topped estimates, but their results do not determine Halozyme’s own performance.
Confirmed
What to watch
- Check reported third-quarter revenue against analysts’ 37.3% year-on-year growth expectation; a shortfall or beat could reshape views of Halozyme’s sales trajectory. Analyst inference
- Look for any update to full-year earnings guidance, meaning management’s forecast for yearly profit; the article says Halozyme beat that estimate last quarter. Analyst inference
- Compare the new results with last quarter’s $481 million revenue and 47.7% annual growth to see whether sales growth is accelerating or slowing. Analyst inference